🇺🇸 Vaxcyte, Inc.PCVX
Get Vaxcyte, Inc. filings on Telegram the moment they are published.
Follow Vaxcyte, Inc. on TelegramOne tap starts your 30-day free trial. No card needed.
Subject: 8-K Items 7.01, 8.01, 9.01
Overview: Reports positive topline results from the OPUS-1 Phase 3 trial of VAX-31, meeting all prespecified primary immunogenicity and safety endpoints.
Source: SEC EDGAR · Original filing
Get filings like this in Telegram the moment they are published — for the companies you follow.
Start 30-day trial About Finterest